TICKERNERD
Menu
TRLVTRLVHealthcare · Drug Manufacturers - Specialty & Generic

TRLV Stock Forecast: Trulieve Cannabis Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
−0.09% on the day

The 7 Wall Street analysts covering Trulieve Cannabis Corp. hold a median 12-month price target of $19 — +68.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
83 / 100
Median analyst target
$19
Analysts covering
7
Revenue$271.0M−10.3% y/y
Operating income$34.8M
Net income−$406.1M
Free cash flow$32.1M
Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.7%
1M
+21.6%
YTD
+30.1%
1Y
+60.0%
From 52W high
−13.0%
From 52W low
+137.6%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TRLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Trulieve Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Issuance
89
Quality
85
Value
71
Momentum
69
Revisions
50
Volatility
40
Growth
38
Size
35

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (38): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TRLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26TRLVHigh $21Median $19Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $15Median $19High $21

The green dot is the last close — the median target sits +68.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
20 July 2026Cantor FitzgeraldInitiatesOverweight$15
20 July 2026Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRLV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TRLV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Trulieve Cannabis Corp. returned +60.0% against +17.5% for the S&P 500, dividends included.

TRLV vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180200Oct 25Jan 26Apr 26Jul 26TRLVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TRLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1756.4%
Analysts raising
0
Analysts cutting
3
Fundamentals

Trulieve Cannabis Corp. (TRLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−18.6×

Cheaper than 96% of US stocks

Price / sales
1.9×

Cheaper than 54% of US stocks

Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
8.1×

Cheaper than 45% of US stocks

Growth & margins
Revenue growth (YoY)
−10.3%

Higher than 15% of US stocks

Earnings growth (YoY)
−10.3%

Higher than 26% of US stocks

Gross margin
59.9%

Higher than 73% of US stocks

Operating margin
12.8%

Higher than 69% of US stocks

Net margin
−41.6%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−47.7%

Higher than 22% of US stocks

Return on assets
3.3%

Higher than 67% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Trulieve Cannabis Corp. (TRLV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Trulieve Cannabis Corp. has a market value of $2.2B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter shrank 10.3% year on year.

  • Net income over the same four quarters: −$476.2M, a −41.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.45.

  • Free cash flow in the twelve months to 30 June 2026: $186.2M, after $50.2M of capital spending.

  • Shares outstanding: 192.4M.

  • Trailing P/E: −18.6×; forward P/E: 20.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Trulieve Cannabis Corp. employs 5,000 people — $228K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

TRLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TRLVTrulieve Cannabis Corp.$2.2B
83
BHCBausch Health Cos., Inc.$2.2B
96
PBHPrestige Consumer Healthcare, Inc.$2.3B
58
ALVOAlvotech$2.1B
29
BCRXBioCryst Pharmaceuticals, Inc.$2.0B
87
SUPNSupernus Pharmaceuticals, Inc.$2.4B
79
PRGOPerrigo Co. Plc$1.9B
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Trulieve Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRLV news & analysis

Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards

Seeking Alpha · 11 Sept 2026positive

Seeking Alpha reinitiated coverage of Trulieve Cannabis Corp. with a Buy rating, citing regulatory catalysts and an attractive valuation following an 81% rally. The potential rescheduling of medicinal cannabis to Schedule III would remove punitive tax burdens, boost cash flows, and offer greater R&D and financing flexibility, with growth anticipated through Florida consolidation, expansion into Texas and Alabama, and possible upside from a $583M tax liability reversal.

Why it matters — TRLV watchers would note the report highlights easing regulatory headwinds and expansion prospects that could support value creation ahead.

Trulieve to Open Medical Cannabis Dispensary in Dunwoody, Georgia

PRNewsWire · 4 Sept 2026positive

Trulieve announced the opening of a new medical cannabis dispensary in Dunwoody, Georgia (DeKalb County), with a grand opening celebration scheduled for Thursday, September 10. The announcement was made on September 4, 2026.

Why it matters — TRLV watchers would care because the new Georgia location represents an expansion of the company's retail footprint in the medical cannabis market.

Trulieve Announces September 2026 Event Participation

PRNewsWire · 2 Sept 2026neutral

Trulieve Cannabis Corp. announced its planned event participation for September 2026, as stated in a Sept. 2 press release. No further details on the specific events were provided in the announcement.

Why it matters — Investors tracking Trulieve may want visibility into the company's upcoming engagements for potential business and brand exposure opportunities.

3 Marijuana Stocks To Focus On For Future Growth And Profits

MarijuanaStocks · 31 Aug 2026neutral

MarijuanaStocks published an article highlighting three marijuana stocks for investors to watch for future growth and profits, noting new laws and market changes present potential opportunities. The piece also acknowledges the sector's high volatility, where even strong company news may not move trading as it does for other public companies.

Why it matters — A TRLV watcher would care because the article points to growth and profit potential in the marijuana sector amid new laws, while also flagging the volatility that can affect cannabis stocks like Trulieve.

Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE

PRNewsWire · 18 Aug 2026positive

Trulieve Cannabis Corp. announced it will ring the Closing Bell at the New York Stock Exchange at 4:00 P.M., marking it as the first U.S. cannabis company listed on the NYSE. The announcement was made by the company, a leading medical cannabis provider in the U.S.

Why it matters — This milestone highlights Trulieve's status as the first U.S. cannabis company listed on the NYSE, underscoring its prominent market position for investors following the company.

FAQ

Frequently asked questions about TRLV stock

What is the TRLV stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Trulieve Cannabis Corp. have a median 12-month price target of $19, with estimates ranging from $15 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRLV stock a buy right now?

Of the 7 analysts covering Trulieve Cannabis Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Trulieve Cannabis Corp. 83 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRLV?

As at 12 Sept 2026, Trulieve Cannabis Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

Will TRLV stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +68.0% from the last close, and Ticker Nerd's factor model ranks Trulieve Cannabis Corp. 83 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRLV stock forecast for 2030?

No analyst covering Trulieve Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $21 over the next 12 months.

How has TRLV stock performed over the past year?

Trulieve Cannabis Corp. returned +60.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Trulieve Cannabis Corp. do?

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures, and retails cannabis products across the United States.

What is the latest news on TRLV?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards". Seeking Alpha reinitiated coverage of Trulieve Cannabis Corp. with a Buy rating, citing regulatory catalysts and an attractive valuation following an 81% rally. The potential rescheduling of medicinal cannabis to Schedule III would remove punitive tax burdens, boost cash flows, and offer greater R&D and financing flexibility, with growth anticipated through Florida consolidation, expansion into Texas and Alabama, and possible upside from a $583M tax liability reversal.

Company

About Trulieve Cannabis Corp.

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures, and retails cannabis products across the United States. The company serves medical patients and adult-use consumers where permitted, using a network of branded dispensaries and home delivery services to distribute its products. Its portfolio includes flowers, edibles, vapes, concentrates, tinctures, topicals, and accessories sold under brands such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One. Trulieve also operates cultivation and processing facilities that support product quality, supply consistency, and in-house production. The company plays a significant role in the U.S. cannabis market, with a strong emphasis on regulated retail, product development, and state-compliant operations.

CEO Ms. Kimberly Rivers J.D. · 5,000 employees · United States · https://www.trulieve.com